Biblio

A. Sehrawat, Gao, L., Wang, Y., Bankhead, A., McWeeney, S. K., King, C. J., Schwartzman, J., Urrutia, J., Bisson, W. H., Coleman, D. J., Joshi, S. K., Kim, D. - H., Sampson, D. A., Weinmann, S., Kallakury, B. V. S., Berry, D. L., Haque, R., Van Den Eeden, S. K., Sharma, S., Bearss, J., Beer, T. M., Thomas, G. V., Heiser, L. M., and Alumkal, J. J., “LSD1 activates a lethal prostate cancer gene network independently of its demethylase function.”, Proc Natl Acad Sci U S A, 2018.

Y. Zhang, Yan, T., Sun, D., Xie, C., Zheng, Y., Zhang, L., Yagai, T., Krausz, K. W., Bisson, W. H., Yang, X., and Gonzalez, F. J., “Structure-activity relationships of the main bioactive constituents of Euodia ruticarpa on aryl hydrocarbon receptor activation and bile acid homeostasis”, Drug Metabolism and Disposition, p. dmd.117.080176, 2018.

A. K. Ehrlich, Pennington, J. M., Bisson, W. H., Kolluri, S., and Kerkvliet, N. I., “TCDD, FICZ, and other high affinity AhR ligands dose-dependently determine the fate of CD4+ T cell differentiation.”, Toxicol Sci, 2018.

W. H. Bisson, Amedei, A., Memeo, L., Forte, S., and Felsher, D. W., “Tumor-Promoting/Associated Inflammation and the Microenvironment: A State of the Science and New Horizons”, Hoboken, NJ, USA: John Wiley & Sons, Inc., 2018, pp. 473 - 510.

G. G. Sharma, Cortinovis, D., Agustoni, F., Arosio, G., Villa, M., Cordani, N., Bidoli, P., Bisson, W. H., Pagni, F., Piazza, R., Gambacorti-Passerini, C., and Mologni, L., “A Compound L1196M/G1202R ALK Mutation in a Patient with ALK-Positive Lung Cancer with Acquired Resistance to Brigatinib Also Confers Primary Resistance to Lorlatinib”, Journal of Thoracic Oncology, vol. 14, no. 11, pp. e257 - e259, 2019.

S. K. Joshi, Bisson, W. H., Qian, K., Huang, A., Watanabe-Smith, K., Tyner, J. W., Davare, M. Ashok, McWeeney, S. K., Tognon, C. E., and Druker, B. J., “Discovery & Characterization of Therapeutically Targetable Ntrk Point Mutations in LeukemiaDisclosures”, Blood, vol. 134, no. Supplement_1, pp. 1256 - 1256, 2019.